Kras mutation in metastatic pancreatic ductal adenocarcinoma: Results of a multicenter phase ii study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (gemoxcet) in first-line therapy

Oncology

Volumn 81, Issue 1, 2011, Pages 3-8

  Kullmann, F ^a,j   Hartmann, A ^b   Stohr R ^b   Messmann, H ^c   Dollinger, M M ^d   Trojan, J ^e   Fuchs, M ^f   Hollerbach, S ^g   Harder, J ^h   Troppmann, M ^a   Kutscheidt, A ⁱ   Endlicher, E ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Academic Teaching Hospital   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f Academic Teaching Hospital   (Germany)

^g Academic Teaching Hospital   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ WiSP Research Institute   (Germany)

^j Kliniken Nordoberpfalz AG   (Germany)

more..

Author keywords

Cetuximab; Chemotherapy; Gemcitabine; KRASmutation; Oxaliplatin; Pancreatic cancer

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; OXALIPLATIN;

ACNE; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CODON; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; FEMALE; GENE MUTATION; HUMAN; KRAS GENE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICRODISSECTION; MULTICENTER STUDY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; POINT MUTATION; PRIORITY JOURNAL; RASH; SKIN TOXICITY; TUMOR GENE; WILD TYPE;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052316938     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000330194     Document Type: Article

References (20)

1. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413. (Pubitemid 27251144)
2. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C: Meta-analysis of randomized trials: Evaluation of benefit from gemictabine- based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8: 82.
3. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartení G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicoló M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F, Gruppo Oncologico Italia Meridionale (GOIM), Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD), Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC): Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: The GIP-1 study J Clin Oncol 2010; 10: 1645-1651.
4. Fjällskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET: Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003; 9: 1469-1473. (Pubitemid 36418403)
5. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Berger HG, Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993; 13: 565-569.
6. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966. (Pubitemid 46972777)
7. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, Mc Conkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6: 1936-1948. (Pubitemid 30305093)
8. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol 2004; 22: 2610-2616. (Pubitemid 41103748)
9. Kullmann F, Hollerbach S, Dollinger MM, Harder J, Fuchs M, Messmann H, Trojan J, Gäbele E, Hinke A, Hollerbach C, Endlicher E: Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in 1st line metastatic pancreatic cancer - a multicenter phase II study. Br J Cancer 2009; 100: 1032-1036.
10. Lurkin I, Stoehr R, Hurst CD, van Tilborg AAG, Knowles MA, Hartmann A, Zwarthoff EC: Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLosONE 2010;5:e8802.
11. Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, Barni S, Di Costanzo F, Dapretto E, Tonini G, Pierantoni C, Artale S, Rota S, Floriani I, Scartozzi M, Zaniboni A, Italian Group for the Study of Digestive Tract Cancer (GISCAD): Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: A randomised, multicentre, phase II trial. Lancet Oncol 2008; 9: 3944.
12. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205. J Clin Oncol 2010; 28: 3605-3610.
13. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-554.
14. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL: K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nuclei Acids Res 1988; 16: 7773-7782.
15. Grünewald K, Lyons J, Fröhlich A, Feichtinger H, Weger RA, Schwab G, Janssen JWG, Bartram CH: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinoma. Int J Cancer 1989; 43: 1037-1041. (Pubitemid 19158034)
16. Immervoll H, Hoem D, Kugarajh K, Steine SJ, Molven A: Molecular analysis of the EGFR- RAS-RAF pathway in pancreatic ductal adenocarcinomas: Lack of mutations in the BRAF and EGFR genes. Virchows Arch 2006; 448: 788-796. (Pubitemid 43824436)
17. Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K, Park JO: Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007; 109: 1561-1569. (Pubitemid 46595692)
18. Boeck SH, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Jung A, Heinemann V: Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) (abstract LBA4011). J Clin Oncol 2010; 28(suppl):18s.
19. da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS: Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer 2010; 116: 5599-5607.
20. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ: Correlation between development of rash and efficacy in patients treated with epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13: 3913-3921. (Pubitemid 47037599)